Sorafenib In Egyptian Patients With Hepatocellular Carcinoma.
Status:
COMPLETED
Trial end date:
2024-03-01
Target enrollment:
Participant gender:
Summary
This study aims to determine the predictive effect of ATG10 and IL6 genetic polymorphisms in safety and efficacy of sorafenib used for the treatment of Egyptian HCC patients. Moreover, this study will determine the association between genetic polymorphisms of ATG10 and IL6 with HCC severity.